Dailypharm Live Search Close

The Effects and Challenges of Vitrakvi

By | translator Choi HeeYoung

21.07.16 06:00:20

°¡³ª´Ù¶ó 0
The first NTRK targeted treatment, same effectiveness as adults in children

Need to verify cancer efficacy

In May, the Cancer Drugs Benefit Appraisal Committee passed, paying attention to whether the drug is listed as an anti-cancer drug that can be treated regardless of cancer type


Bayer's "Vitrakvi" has been able to treat cancer patients who are positive for NTRK gene fusion, regardless of cancer type.


The NTRK gene plays an essential role in the physiology, development and function of the nervous system through the TRK protein, which causes problems when unrelated genes are combined. This phenomenon, called NTRK gene fusion, produces a fusion TRK protein that transmits abnormal signals. Eventually, the downstream pathway becomes hyperactive, causing problems in cell growth and survival, leading to cancer.

All cancers can be caused by NTRK gene fusion, but they vary in frequency from cancer to cancer. There are very few cases of NTRK gene fusion in commonly

(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)